KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash & Equivalents (2016 - 2025)

Astrazeneca has reported Cash & Equivalents over the past 11 years, most recently at $5.7 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $5.7 billion for Q4 2025, up 370.04% from a year ago — trailing twelve months through Dec 2025 was $5.7 billion (up 370.04% YoY), and the annual figure for FY2025 was $5.7 billion, up 370.04%.
  • Cash & Equivalents for Q4 2025 was $5.7 billion at Astrazeneca, up from $1.2 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for AZN hit a ceiling of $6.3 billion in Q4 2021 and a floor of $1.2 billion in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $5.8 billion (2023), compared with a mean of $5.1 billion.
  • Biggest five-year swings in Cash & Equivalents: soared 435.45% in 2021 and later tumbled 79.2% in 2024.
  • Astrazeneca's Cash & Equivalents stood at $6.3 billion in 2021, then dropped by 2.58% to $6.2 billion in 2022, then dropped by 5.29% to $5.8 billion in 2023, then tumbled by 79.2% to $1.2 billion in 2024, then skyrocketed by 370.04% to $5.7 billion in 2025.
  • The last three reported values for Cash & Equivalents were $5.7 billion (Q4 2025), $1.2 billion (Q4 2024), and $5.8 billion (Q4 2023) per Business Quant data.